Member Info for Aldebaran

One4one beware of everyone on these boards. End of the day were all just anonymous names on a screen. As you'll see here Touk has zero credibility, neither does Wyn whos opinions change based on their trading positions at any one time.

LFT's was a completely different time and management team, resigned to history last year as the current CEO sold off the the last bit of that business. It was incidentally our only source of revenue and on verge of profitability so selling it off to focus solely on the non revenue generating oncology pipeline only shows you just how confident the management team are in it.

It also shows you how the likes of Touk cant let go of the past, even though its totally irrelevant to the current circumstance. He gets these ideas in his head and cant let go of them, like their being a 10p placing, like the drugs having a half life problem etc... it doesn't matter how many times sane, rational informed investors and even expert scientists try and educate him. He just doesnt get it.

Like I said, long term holders here were early but not wrong. Touk is consistently wrong and embarrassed himself regularly as you'll see over and over again if you stick around. Case in point his master trade last week where he sold at 75p only for shares to continue rising on strong volume. He's probably hoping to buy then back for 10p.

He's now shamelessly bringing Christina's credibility into question based of the misleading done by a former CEO regarding a part of Avacta that no longer exists. I honestly dont know how he dare. If Christina is lying to us about these results then all of the scientific advisory board, the FDA, our entire board including NED's have fell for it too. The NED's threw £550k of there own money at this only a few weeks ago the suckers!

It woud also mean oncologists at multiple cancer treatment centres across the UK and USA are in on it the big ribena scam too.

If its not all a lie though, and Christina is telling the truth. We're on the verge of a true paradigm shift in oncology. It's as big as that. Do the research and decide for yourself. Don't trust anyone here. Especially not low IQ posters like touk, who has now just found his way into my bin 👍

Good luck

One4one you seem a smart chap one who does his own research and doesnt need lecturing on what or how much to invest in anything. If you listened to the likes of Touk, you'd still be waiting for a 10p placing. Were now 750% up from that point and climbing.

CC's job is to promote the company but not to lie. She has hit every milestone she has laid out and has bags of integrity. Not only that be has oversight from the board including one Mr Richard Hughes who recently invested £500k of his own money into this - no small change for anyone.

Note a lot as changed in a year or so if your looking back. Primarily we have 2 clinical assets now, no quarterly CLN payments, funding until 2027, leaked presentation to Novartis and a shed ton more exceptional data not to mention the FDA have removed the lifetime limit of dox because of how good pre|CISION is. People including me even were excited years ago and predicting tens of billions of pounds or at least bilions of pounds buyouts. We were early not wrong. Touk was clearly wrong about the placing and has been embarrassed at a technical level multiple times over. He spent best part of 2025 fretting about the half life of ava6000 despite how exceptionally well it was performing and despite both the CEO and CSO clearly stating it wasn't an issue. I dont know, I think he might be still fretting about that today.

Anyway, good luck with your research, let us all know if you need anything clearing up and the only bit of advice id give you is dont want for 10p.

The investment case has only got stronger and stronger. ✌🏾

I forgot the data was so good the FDA were shocked and asked for it all to be rechecked! 😁

They've seen been encouraging to say the least with regards AVA6103. Pushing against an open door or words to that effect Francis said.

Good couple months coming up here 😁

Https://x.com/i/status/2045422306894225489

Its here also on X and has been for hours. Its everywhere. To request a source for this is a bit pathetic.

Straight off hormuz shut again. Oil up, gold down..yawn.

Shouldn't even impact us here given the 1400 aisc

Present in 90% of solid tumours almost ubiquitous unlike all other drugs which only target specific antigen therefore are limited in their applicability.

FAP present in stroma around the tumours like mortar around bricks. Other drugs that target cell antigen lose effect overtime as they kill cells because their target is lost.

AVACTA's PDC doesnt bind to FAP either, it uses FAP to cleave or snip the warhead and the warhead is then live again and permeates into nearby cancer cells and destroys them. Other drugs DO bind to their target and need complicated internalisation mechanisms. Ours don't.

The PDC is exquisitely cleaved by FAP and nothing else, no other closely related enzymes meaning we dont see off target toxicity and this translates into much improved patient tolerability AND significant concentration of the drug where it needs to be leading to improved efficacy.

Using avactas technique, undetected metasistis are also cleaned up before they can become a issue.

Manufacturing a PDC costs 1/10th of what it costs to make an ADC.

Avacta have cracked it. A kinder treatment that is more efficacious, more broadly applicable and cheaper than anything else on the market. Multiple blockbuster drugs will come from this platform I have zero doubt.

Aim is thick as mince for not valuing this at multiples already. It is amazing that private investors have sussed this out way before smart money and specialist biotech professionals have figured it out. Unless of course, its been ribena all along.

2 scenarios its an £XXBn company or its worthless

Also, FYI, when dosing with precision drugs, they also "clean up" any undetected metastisis.

The drugs are 10x cheaper to manufacture than ADC's also plus big far have some major patents expiring in the next few years. Precision is perfect for them.

Good look with your research into avacta

Welcome.

Yes im a nutshell that is it. Bit more info is they can target almost any drug to FAP, not just chemo. FAP is found in 90% of solid tumours and barely anywhere else in the body making it a perfect target.

Also, FAP is present in the stroma, not in the tumour so as the tumor dies, we dont lose the target meaning efficacy is sustained.

Finally, the system avacta use deposits drugs at a ratio of 100 - 1 meaning almost no exposure to healthy cells. Treat the cancer, spare the patient.

Market opportunity is in hundreds of billions

Pretty simple really. If im on the team knowing how well its going and friends or former good colleagues ask how things are going. Politely respond saying you cant talk about it but give a big smile and raise your eyebrows whilst looking then in the eye. No rules broken.

One of the main reasons for these conferences is for people in the industry to go spot the next big thing early and invest. A story played out the same over and over. Its avactas time now. Right now. Were in it.

Well, let us recap on what we already know

- moa proven even at low FAP environment

- intratumoral extecan present above ic90 line for days with absolutely rapid plasma clearance (4hrs max)

- tumor plasma ratio 99-1 leading to MINIMAL healthy tissue exposure

- 7/8 complete responses in sarcoma

- 4/4 complete responses in gastric

Plus others I cant remember but I do remember the responses were durable and occurred after ONLY 3 doses!!

- 75x increase in MTD

So what to expect or anticipate from AACR ?

More animal models with different tumors showing utility of the topo1i across the broad range of tumors

Durability of responses increased further as we have more data for existing animals

More details on slow release and translational implications

And then importantly I think avacta are professional enough not to purposely leak classified ongoing clinical results... but the odd smile can mean a hell of a lot. If it really is working and it seems to be from Christina's confidence then I am expecting around or shortly after AACR we start seeing some big purchases

-

So we are going to get updated pre clinical data for pre|CISION extecan. Wonder if the people at conference will be given nod or wink about how the clinical trial is going. Maybe just a wry smile would be enough to see a influx, of buying activity.

Maybe the outstanding animal data alone combined with the 4yrs data for ava6000 will be enough. If I can put 2 and 2 together and join the dots surely the clever folk at this conference can and will. About time the valuation of this company started to reflect the actual IP value

Good post JHFH. Very balanced.

Only puzzle for me is why did Vlad so publicly laud the results of P1 back in August saying clearly they are alive and doing well but nothing since?

So HEMO can release that news but have chosen not to. I belief its because patients have passed away but yes I may be incorrect I accept that.

It is immaterial to the trial if they have passed away as it is highly unlikely first and lowest dose is a miracle cure now and this p1 is just about safety so it matters not from a trial POV but some here like TraderRicky et al go around claiming patients are definitely alive and its a miracle blah blah..if it was the SP simply wouldn't be wear it is and Vlad would be screaming it from the roof tops.

Excellent chance that efficacy is seen as dose increases though and agree with you about a pediatric and social media! 👍

If you do lobby vlad and speak to him, just ask him for a bloody roadmap will you and genuinely see if he can do a series of informative videos like the company that shall not be named. It costs sweet FA and would do wonders for PR.

I do not buy it that he doesnt have time. Start focusing more on investor relations and you might get a new fresh wave of investors onboard, including me. Right now I just see hemo as promising but very early science and a completely unclear clinical/commercial timeline or strategy. A investment is more then just about the science 👍

Good luck

With Avacta now up over 20% from recent placing on rising volume and strength going into a news rich period with FDA approvals, data releases and commercial deals (all signposted by the ceo) and hemo down 15% over same period i do wonder if the likes of micky and trader Ricky plus others have actually seen the light and are selling hemo to buy avacta? Perhaps their are some high IQ people here after all 🤔

Ade of course it will be sold of. Its just so obvious. You seem to me like a smart reasonable fellow. Check out avacta and tell me it doesnt knock the socks off AFC on every metric.

The chart alone is breaking out in a clear uptrend on volume. Make yourself some money lad

Why is anyone with a reasoned approach to investing considered a SHORTER here lol

Why is it we are having to piece puzzles together to see whats happening. This isnt a game if cluedo.

500k shares already traded today.

Since placing announced we've churned through 39.5m almost 3x placing volume and price is UP 20%

Not to shabby

The pediatric cohort and p4 adult should of been dosed 7 months ago never mind ready to go.

Dose them then initiate tech transfer while the safety and efficacy data on these patients matures.

Vlad is running a PLC, he needs to at some point start acting like a CEO instead of a scientist. Why are hemo recruiting another scientist, they need commercial and communications people surely not more science people

Yeah, smart are ses will be saying the same to you in a few years m8 😅

Seen and heard it all before, doesnt seem like you have so you'll learn the hard way 🤷🏽‍♂️

Ive been invested years. YEARS. from before covid.

Only have a small position left here now as a placeholder to keep me interested. I read all the RNS, watch the webinars and interviews, attended AGM even under bond and said to myself I would not get hyped into this again.

I broke my own rule and added a small amount when komatsu rns came out with talk of accelerated revenues but as usually were since disappointed by the fuel cell sales targets for this year.

It always just out of reach. Always tomorrow. Hydrogen is always the future. Well, were in that future I thought of 7 years ago and guess what, NOTHINGS CHANGED.

Well, John has came in and made changes and I belief in him but still a long, expensive and dangerous but exciting road ahead.

Does that answer your question? Not that it should matter if I invested or not. Play the ball not the man

Many of you are to in love with AFC and to blinded by your own bias to see I am right and have been consistently right.

Because you dont like what I say it doesnt make it untrue.

Tell me, what is the point in using these bulletin boards if it isn't to collate others opinions and learn plus share information that could make you or save you money?

I am so sick of seeing retail get rinsed on stocks like this. Over and over and over again.